Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer
NCT ID: NCT00193167
Last Updated: 2011-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
2004-01-31
2006-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
NCT00002933
Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer
NCT00021268
A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma
NCT00215956
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
NCT01607957
Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer
NCT00016250
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Topotecan
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Topotecan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Metastatic colorectal cancer
* One previous chemotherapy for metastatic disease
* Measurable or evaluable disease
* Able to perform activities of daily living with assistance
* Adequate bone marrow, liver, and kidney function
* All patients must give written informed consent prior to study entry.
Exclusion Criteria
* Brain or meningeal involvement
* Serious active infection or underlying medical conditions
* Other active neoplasms are ineligible
* Pregnant or lactating
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
SCRI Development Innovations, LLC
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
SCRI
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anthony Greco, MD
Role: PRINCIPAL_INVESTIGATOR
SCRI Development Innovations, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tennessee Oncology
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
104864724
Identifier Type: -
Identifier Source: secondary_id
SCRI GI 56
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.